We are live on
!
Find out more
CFA
Camarda Financial Advisors Portfolio holdings
AUM
$190M
1-Year Est. Return
48.71%
This Fund
S&P 500
This Quarter
Est. Return
+5.93%
1 Year Est. Return
+48.71%
3 Year Est. Return
+132.11%
5 Year Est. Return
+247.64%
10 Year Est. Return
+511.39%
AUM
$146M
AUM Growth
+$15.5M
(+12%)
Cap. Flow
+$8.33M
Cap. Flow
% of AUM
5.71%
Top 10 Holdings %
Top 10 Hldgs %
38.14%
Holding
245
New
42
Increased
60
Reduced
53
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FM
iShares Frontier and Select EM ETF
FM
|
+$3.06M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$1.05M |
| 3 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$490K |
| 4 |
Columbia Emerging Markets Consumer ETF
ECON
|
+$351K |
| 5 |
iShares MSCI EAFE Small-Cap ETF
SCZ
|
+$330K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$468K |
| 2 |
Apple
AAPL
|
+$349K |
| 3 |
Macy's
M
|
+$319K |
| 4 |
GLOG
GASLOG LTD
GLOG
|
+$307K |
| 5 |
Bank of America
BAC
|
+$221K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 12.37% |
| 2 | Energy | 6.72% |
| 3 | Industrials | 5.18% |
| 4 | Technology | 4.65% |
| 5 | Financials | 4.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Snap-on
SNA
$21.7B
| $2.15M | 1.47% |
18,106
-674
| -4% | -$77.9K |
|
|
27
Apple
AAPL
$4.99T
| $2.14M | 1.47% |
92,216
-16,424
| -15% | -$349K |
|
|
ESRX
28
DELISTED
Express Scripts Holding Company
ESRX
| $2.1M | 1.44% |
30,277
-545
| -2% | -$38.4K |
|
29
iShares Morningstar Small-Cap Value ETF
ISCV
$701M
| $2.03M | 1.39% |
47,631
+2,202
| +5% | +$90.7K |
|
30
APA Corp
APA
$12.3B
| $1.98M | 1.36% |
19,666
-403
| -2% | -$36.5K |
|
31
iShares Select Dividend ETF
DVY
$24.1B
| $1.95M | 1.34% |
25,351
+540
| +2% | +$40.4K |
|
32
Capital One
COF
$130B
| $1.94M | 1.33% |
23,426
-406
| -2% | -$31.5K |
|
33
Baxter International
BAX
$12.6B
| $1.86M | 1.27% |
47,297
-1,162
| -2% | -$46.5K |
|
34
Western Union
WU
$2.58B
| $1.82M | 1.25% |
105,211
-440
| -0.4% | -$7.11K |
|
35
Accenture
ACN
$101B
| $1.81M | 1.24% |
22,359
-291
| -1% | -$23.4K |
|
36
Thomson Reuters
TRI
$45.1B
| $1.76M | 1.21% |
41,832
-311
| -0.7% | -$12.7K |
|
|
MBT
37
DELISTED
Mobile TeleSystems Public Joint Stock Company American Depositary Shares (Each representing 2 Shares
MBT
| $1.68M | 1.15% |
85,101
-177
| -0.2% | -$3.16K |
|
38
Rogers Communications
RCI
$18.8B
| $1.6M | 1.1% |
39,791
-37
| -0.1% | -$1.5K |
|
39
Merck
MRK
$326B
| $1.48M | 1.01% |
26,739
+3,928
| +17% | +$214K |
|
40
Invesco S&P MidCap 400 Pure Growth ETF
RFG
$339M
| $1.44M | 0.98% |
57,220
+6,345
| +12% | +$153K |
|
41
Vanguard Small-Cap Growth ETF
VBK
$23.2B
| $1.03M | 0.71% |
8,112
+698
| +9% | +$84.7K |
|
|
42
Bristol-Myers Squibb
BMY
$130B
| $1.03M | 0.71% |
+21,261
| New | +$1.05M |
|
43
Pfizer
PFE
$144B
| $901K | 0.62% |
32,011
+7,160
| +29% | +$204K |
|
44
Jazz Pharmaceuticals
JAZZ
$16.1B
| $605K | 0.41% |
4,114
-1,318
| -24% | -$183K |
|
|
QCOR
45
DELISTED
QUESTCOR PHARMA INC
QCOR
| $591K | 0.41% |
6,385
-1,173
| -16% | -$100K |
|
46
AT&T
T
$169B
| $569K | 0.39% |
21,306
+11,367
| +114% | +$304K |
|
|
AGN
47
DELISTED
Allergan plc
AGN
| $556K | 0.38% |
2,494
-768
| -24% | -$159K |
|
48
TD Synnex
SNX
$19.8B
| $532K | 0.36% |
14,600
-4,604
| -24% | -$155K |
|
49
McKesson
MCK
$104B
| $531K | 0.36% |
2,853
-719
| -20% | -$128K |
|
50
Deluxe
DLX
$1.25B
| $514K | 0.35% |
8,766
-2,533
| -22% | -$138K |
|
Similar funds
HCM
RCAP
WSL
BC
SCM
BCPWM
CCA
LWP
Camarda Financial Advisors's Q2 2014 Portfolio in Review
As of Q2 2014, Camarda Financial Advisors held 245 positions worth $146M, up 12% from $130M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Camarda Financial Advisors deployed $8.33M of net new capital in Q2 2014, opening 42 new positions and adding to 60 existing holdings. Its largest new stake was Bristol-Myers Squibb: 21,261 shares worth $1.03M.
By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 13% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was Amgen, an estimated $468K trimmed.
- Camarda Financial Advisors's largest Q2 2014 buy was Bristol-Myers Squibb: 21,261 shares worth $1.03M.
- Camarda Financial Advisors added most to iShares Frontier and Select EM ETF in Q2 2014, an estimated $3.06M increase.
- Camarda Financial Advisors's biggest Q2 2014 reduction was Amgen, cutting an estimated $468K.
- Camarda Financial Advisors fully exited Macy's in Q2 2014, selling an estimated $319K.
- Camarda Financial Advisors's ten largest holdings make up 38% of its $146M portfolio in Q2 2014.
- Camarda Financial Advisors opened 42 new positions and closed 25 in Q2 2014.
- Camarda Financial Advisors's portfolio value rose 12% quarter-over-quarter to $146M.
Based on Camarda Financial Advisors's 13F filing for Q2 2014, filed 11 Jul 2014.